"The Supreme Court on Wednesday is expected to decide whether to grant a stay of a lower-court ruling that would revoke approval for the abortion medication mifepristone. If it fails to do so, it would betray not only decades of science supporting the safety of the drug but also the broader authority of the Food and Drug Administration. [snip]
"To me, the question before the Supreme Court hinges on this point: Does
it recognize the authority that Congress entrusted the FDA’s scientists
and clinicians to represent the public’s interest and approve drugs
based on evidence and long-established procedures, or not? Mifepristone
must be treated like all other pharmaceutical products reviewed by the
FDA, just as reproductive care must be treated like any other aspects of
health care." -- Dr. Lena S. Wen, in the Washington Post, on what's at stake today and going forward should the Republican Supreme Court take action that would be injurious to the health of women and to the authority of the FDA to regulate pharmaceuticals.
No comments:
Post a Comment